Research and Development

The core of our business is to research, develop and optimize clinical testing processes to give your ophthalmic research program the greatest chance of success.

Ora’s 40 years of R&D focus has led to the development of the most successful clinical models for studying ophthalmic disease, such as our CACsm, CAEsm, and Allergen BioCubesm.
Ora continues to develop novel endpoints that are more precise, reproducible and clinically relevant, enabling better patient selection and more sensitive identification of drug effects.
Future Research
Ora’s investment in R&D continues to advance clinical models and methods that will pave the way in meeting patient demands for new drugs and products across an array of ophthalmic indications.

At Ora, we’ve spent over 40 years conducting ongoing, internally funded research to develop models and endpoints that consistently and reliably identify patient populations and assess the efficacy of a drug.

We’ve done our research so our client’s drug, drug delivery or medical device research program enters the preclinical and clinical pathways with the greatest chance of success.

Led by Keith Lane, our Research and Development team is comprised of biostatisticians, computer scientists, biomedical engineers, and clinical research professionals who understand that not all therapies work the same way and, therefore, not all clinical study designs should include the same methods and procedures.

Customization is the key to our services and our clients’ success. Utilizing Ora’s own advanced clinical models, diagnostic tools and clinical scales, we’re able to provide a fully customized protocol to reflect your drug’s specific mechanism of action, target population, and efficacy profile.


At Ora, we focus on gaining a more comprehensive understanding of the pathology and physiology of a disease; marrying the underlying science of a condition with how we approach testing the methodologies and models for studying that disease in the clinic.

We customize our models based on the therapy being studied, using our own diagnostic methods to characterize patient subtypes. Our belief is that a drug should address the signs and symptoms of a disease. Using our proprietary methods, we can ensure that patients selected for study inclusion display both a sign and a symptom of a specific disease to better assess the efficacy of a drug or treatment.

Ora’s commitment to translational research enables our R&D Team to consistently refine our current models, while being highly responsive to the latest scientific advances and client requests for customization. As we look toward the future, Ora’s commitment to internal research and development will pave the way towards meeting patient demands for new drugs and products across an array of ophthalmic indications.